SEC Form 4 · accession 0001178913-17-001170
ORAMED PHARMACEUTICALS INC. · ORMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Miriam Kidron
Officer — Chief Scientific Officer · Director
Period of report
Apr 19, 2017
Accepted (ET)
Apr 19, 2017 · 5:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001176309
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Apr 19, 2017 | S | 52,814 | $6.33 | D | 89,636 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares were sold to Li Xiapeng, a director of Oramed Pharmaceuticals Inc.
- F2Consists of 89,636 shares of Common Stock underlying vested Restricted Stock Units that are issuable upon request.